By Denny Jacob
Lexicon Pharmaceuticals Inc. shares dropped 11% to $1.69 in after-hours trading after the company said it didn’t reach statistical significance on the primary endpoint of its Phase 2 study of LX9211 in postherpetic neuralgia.
The biopharmaceutical company said that despite the primary endpoint not reaching statistical significance, overall study results demonstrated evidence of effect.
“These results bolster our confidence in moving the LX9211 clinical program forward in hopes of delivering a potential solution for neuropathic pain patients in need of additional treatment options,” said Chief Medical Officer Craig Granowitz.
Write to Denny Jacob at denny.jacob@wsj.com
